RecruitingNot ApplicableNCT04571658

NEPTUNE Match Study

Implementing Precision Medicine for Glomerular Diseases in the Nephrotic Syndrome Study Network (NEPTUNE)

Sponsor

University of Michigan

Enrollment

375 participants

Start Date

May 2, 2022

Study Type

INTERVENTIONAL

Conditions

Nephrotic Syndrome in Children Alport Syndrome Focal Segmental Glomerulosclerosis Membranous Nephropathy Minimal Change Disease Minimal Change Nephrotic Syndrome FSGS MCD MCD - Minimal Change Disease

Summary

NEPTUNE Match is an additional opportunity offered to NEPTUNE study participants to prospectively recruit and communicate patient-specific clinical trial matching with kidney patients and their physician investigators.

Eligibility

Min Age: 1 YearMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

The NEPTUNE Match Study helps connect patients who are already participating in the NEPTUNE kidney disease research study with relevant clinical trials based on their specific test results and biomarkers. NEPTUNE is a research network that studies rare kidney diseases including nephrotic syndrome — a condition where the kidneys leak large amounts of protein. This study creates a personalized pathway to link these patients with treatments being tested specifically for their disease type. This is not a treatment study itself — it is a matching program that identifies which NEPTUNE participants might benefit from joining an available clinical trial. You may be eligible if: - You are already enrolled in the NEPTUNE observational study - You receive nephrology care at a NEPTUNE study site - You speak English or Spanish - You are willing and able to consent to participation You may NOT be eligible if: - You are not currently a NEPTUNE observational study participant - You speak neither English nor Spanish Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERCommunication

The NEPTUNE Match study includes an interdisciplinary Communication Team that will translate findings from the Molecular Nephrology Board (MNB) to inform patients of the matching assessment with ongoing clinical trials. This team has considerable experience with conveying complex biomedical research information to patients and families and includes experts in precision nephrology, nephrology patient \[adult and pediatric\] communication, and health education.

Locations(16)

Emory University Hospital - Children's Hospital of Atlanta

Atlanta, Georgia, United States

John H. Stroger, Jr., Hospital of Cook County

Chicago, Illinois, United States

University of Kansas Medical Center

Kansas City, Kansas, United States

Johns Hopkins Medicine

Baltimore, Maryland, United States

University of Michigan

Ann Arbor, Michigan, United States

Children's Mercy Hospital

Kansas City, Missouri, United States

Northwell/Cohen's Children's Hospital

New Hyde Park, New York, United States

Columbia University Medical Center

New York, New York, United States

University of North Carolina Chapel Hill

Chapel Hill, North Carolina, United States

Cleveland Clinic Foundation

Cleveland, Ohio, United States

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Temple University

Philadelphia, Pennsylvania, United States

Medical University of South Carolina

Charlotte, South Carolina, United States

Seattle Children's Hospital

Seattle, Washington, United States

University of Washington Medical Center

Seattle, Washington, United States

Providence Sacred Heart Medical Center

Spokane, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04571658

Related Trials

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis

NCT066648141 location

Belimumab With Rituximab for Primary Membranous Nephropathy

NCT0394985520 locations

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

NCT07220083266 locations

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

NCT0500398647 locations

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

NCT0650070269 locations